Vælg sprog

da
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

Danske
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

Hvordan foretrækker du at finansierer din konto?

* Vi opkræver ingen kommission for at foretage indbetalinger på din konto

Biogen

BIIB.US $ 221.99 USD

-1.69 $ (-0.76%)

Vækstpotentiale

30.53%

Udbytteindkomst

1d
1u
1 måned
6 måneder
Hele tiden

Tilføj til kurv

1 lot = 1 aktie

Købsbeløb:

Mæglerkommission:

Overførselsgebyr:

Anbefaling

Strong Buy

Præstationsbedømmelse

DCF

228.77

ROE

0.37

ROA

0.16

P/S

3.38

P/B

4.25

Debt / Equity

0.73

Om virksomheden

American Biogen Inc. is a global leader in biotechnology, engaged in scientific research and development of a wide range of medications for treatment of people with hematological, neuralgic and autoimmune diseases. As of today, Biogen is the third largest biotech company in the world. Company's financial gain as of 2015 equaled almost $ 3 billion. Scientific centers and hubs of Biogen Inc. are allocated in over 30 countries, where about 8,000 employees are engaged in various activities. One of the latest projects is Alprolix. It gained a worldwide recognition no more than a year after its first release in 2014 and was highly appraised by Medical Reviewers. Alprolix prevents most fatal bleedings and acts as a prophylactic agent for people with hemophilia.


Tilmeld dig investeringsideer fra Freedom Finance-analytikere

Vi sender en e-mail en gang om ugen, der kun indeholder de mest relevante og vigtige oplysninger

Tillykke!

Nu vil du altid være opmærksom på, hvilke aktier der er mere rentable at investere i